Ignite Creation Date:
2024-05-06 @ 2:54 PM
Last Modification Date:
2024-10-26 @ 1:39 PM
Study NCT ID:
NCT04460430
Status:
TERMINATED
Last Update Posted:
2022-10-25
First Post:
2020-06-29
Brief Title:
Targeting EGFRERBB2 With Neratinib in Hormone Receptor HR-PositiveHER2-negative HER2-enriched AdvancedMetastatic Breast Cancer
Sponsor:
Organization:
SOLTI Breast Cancer Research Group
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
12
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: